Results 311 to 320 of about 420,842 (369)

Recombinant Hypoallergenic Cat Allergy Vaccines

Allergy, EarlyView.
This study reports the construction and preclinical characterization of peptide‐carrier‐based vaccines combining all three important cat allergens (Fel d 1, Fel d 4 and Fel d 7) within single vaccine antigens, termed PreS‐Cat 1‐PreS‐Cat 5. Two subcutaneous immunizations of rabbits with PreS‐Cat 1‐5 induce equal or better antibodies blocking allergic ...
Daria Trifonova, Mirela Curin, Margarete Focke‐Tejkl, Zicheng Liu, Kristina Borochova, Pia Gattinger, Marianne van Hage, Hans Grönlund, Renata Kiss, Huey‐Jy Huang, Walter Keller, Ksenja Riabova, Antonina Karsonova, Michael Kundi, Inna Tulaeva, Daria Fomina, Alexander Karaulov, Rudolf Valenta   +17 more
wiley   +1 more source

Conundrum of Acute Liver Failure.

Ann Afr Med
Vishnu BS, Teja BSS, Sri IL, Ganti E.
europepmc   +1 more source

Nephrotic Syndrome: Beyond Common Causes. [PDF]

Nephrology (Carlton)
Hazim H, Horn R, Varikara AK, Mesure J, Chacko B.   +4 more
europepmc   +1 more source

Total Neoadjuvant Therapy Versus Conventional Neoadjuvant Therapy for Rectal Cancer: Cost Analysis in a Public Healthcare System

ANZ Journal of Surgery, EarlyView.
Costs of neoadjuvant therapy. ABSTRACT Purpose Total neoadjuvant therapy (TNT) has become the standard of care in locally advanced rectal cancer, but its economic impact is unclear. This study compares the cost of TNT with conventional neoadjuvant therapy (CNT), consisting of either short‐course radiotherapy or long‐course chemoradiotherapy, within a ...
Ishraq Murshed, Sergei Bedrikovetski, Ishmam Murshed, Zachary Bunjo, Tracy Fitzsimmons, Michelle Thomas, Tarik Sammour   +6 more
wiley   +1 more source

Tissue Determinants of Antiviral Immunity in the Liver. [PDF]

Z Gastroenterol
Wohlleber D, Knolle PA.
europepmc   +1 more source

Liver transplantation [PDF]

, 1991
Gordon, RD, Starzl, TE, Todo, S, Tzakis, AG   +3 more
core  

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non‐Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group

British Journal of Haematology, EarlyView.
Summary Developing new therapeutic regimens for relapsed/refractory (R/R) B non‐Hodgkin lymphoma (NHL) patients remains a significant unmet clinical need. Our objective was to evaluate atezolizumab (ATE), obinutuzumab (OBI) and venetoclax (VEN) combination in patients with R/R NHL who had received at least one prior anti‐CD20‐containing ...
Charles Herbaux, Emmanuel Bachy, Reda Bouabdallah, Stéphanie Guidez, Olivier Casasnovas, Pierre Feugier, Gandhi Damaj, Hervé Tilly, Loïc Ysebaert, Steven Le Gouill, Nadine Morineau, Emmanuel Gyan, Rémy Gressin, Roch Houot, Morgane Cheminant, Franck Morschhauser, Catherine Thieblemont, Corinne Haioun, Emmanuelle Nicolas‐Virelizier, Luc‐Matthieu Fornecker, Nicolas Daguindau, Guillaume Cartron   +21 more
wiley   +1 more source

Hepatitis B serosurvey to validate the achievement of regional hepatitis B control targets in Belarus. [PDF]

Vaccine
Vysotskaya V, Gassowski M, Kasper A, Gasich E, Kolomiets N, Dashkevich A, Wannemuehler K, Dubovik O, Mosina L.   +8 more
europepmc   +1 more source

Innovative pharmacotherapy for hepatic metabolic and chronic inflammatory diseases in China

British Journal of Pharmacology, EarlyView.
Abstract Liver disease constitutes a significant global health concern, particularly in China where it has distinctive characteristics. China grapples with a staggering 300 million cases, predominantly due to hepatitis B and metabolic non‐alcoholic fatty liver disease. Additionally, hepatocellular carcinoma has become a prevalent which is a lethal type
Feng Zhang, Jiaming Ju, Hongtao Diao, Jinglun Song, Yu bian, Baofeng Yang   +5 more
wiley   +1 more source

Molecular and serological investigation of hepatitis B virus in patients with acute undifferentiated febrile illness at Tha Song Yang hospital, Tak Province, Thailand. [PDF]

BMC Infect Dis
Thippornchai N, Sae-Oueng A, Jittmittraphap A, Nguitragool W, Leaungwutiwong P.   +4 more
europepmc   +1 more source